• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

理解临床医生如何在早期脓毒症管理中个性化液体和血管加压药决策。

Understanding How Clinicians Personalize Fluid and Vasopressor Decisions in Early Sepsis Management.

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor.

VA Center for Clinical Management Research, Ann Arbor, Michigan.

出版信息

JAMA Netw Open. 2024 Apr 1;7(4):e247480. doi: 10.1001/jamanetworkopen.2024.7480.

DOI:10.1001/jamanetworkopen.2024.7480
PMID:38639934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11031682/
Abstract

IMPORTANCE

Recent sepsis trials suggest that fluid-liberal vs fluid-restrictive resuscitation has similar outcomes. These trials used generalized approaches to resuscitation, and little is known about how clinicians personalize fluid and vasopressor administration in practice.

OBJECTIVE

To understand how clinicians personalize decisions about resuscitation in practice.

DESIGN, SETTING, AND PARTICIPANTS: This survey study of US clinicians in the Society of Critical Care Medicine membership roster was conducted from November 2022 to January 2023. Surveys contained 10 vignettes of patients with sepsis where pertinent clinical factors (eg, fluid received and volume status) were randomized. Respondents selected the next steps in management. Data analysis was conducted from February to September 2023.

EXPOSURE

Online Qualtrics clinical vignette survey.

MAIN OUTCOMES AND MEASURES

Using multivariable logistic regression, the associations of clinical factors with decisions about fluid administration, vasopressor initiation, and vasopressor route were tested. Results are presented as adjusted proportions with 95% CIs.

RESULTS

Among 11 203 invited clinicians, 550 (4.9%; 261 men [47.5%] and 192 women [34.9%]; 173 with >15 years of practice [31.5%]) completed at least 1 vignette and were included. A majority were physicians (337 respondents [61.3%]) and critical care trained (369 respondents [67.1%]). Fluid volume already received by a patient was associated with resuscitation decisions. After 1 L of fluid, an adjusted 82.5% (95% CI, 80.2%-84.8%) of respondents prescribed additional fluid and an adjusted 55.0% (95% CI, 51.9%-58.1%) initiated vasopressors. After 5 L of fluid, an adjusted 17.5% (95% CI, 15.1%-19.9%) of respondents prescribed more fluid while an adjusted 92.7% (95% CI, 91.1%-94.3%) initiated vasopressors. More respondents prescribed fluid when the patient examination found dry vs wet (ie, overloaded) volume status (adjusted proportion, 66.9% [95% CI, 62.5%-71.2%] vs adjusted proportion, 26.5% [95% CI, 22.3%-30.6%]). Medical history, respiratory status, lactate trend, and acute kidney injury had small associations with fluid and vasopressor decisions. In 1023 of 1127 vignettes (90.8%) where the patient did not have central access, respondents were willing to start vasopressors through a peripheral intravenous catheter. In cases where patients were already receiving peripheral norepinephrine, respondents were more likely to place a central line at higher norepinephrine doses of 0.5 µg/kg/min (adjusted proportion, 78.0%; 95% CI, 74.7%-81.2%) vs 0.08 µg/kg/min (adjusted proportion, 25.2%; 95% CI, 21.8%-28.5%) and after 24 hours (adjusted proportion, 59.5%; 95% CI, 56.6%-62.5%) vs 8 hours (adjusted proportion, 47.1%; 95% CI, 44.0%-50.1%).

CONCLUSIONS AND RELEVANCE

These findings suggest that fluid volume received is the predominant factor associated with ongoing fluid and vasopressor decisions, outweighing many other clinical factors. Peripheral vasopressor use is common. Future studies aimed at personalizing resuscitation must account for fluid volumes and should incorporate specific tools to help clinicians personalize resuscitation.

摘要

重要性

最近的脓毒症试验表明,液体自由复苏与液体限制复苏具有相似的结果。这些试验采用了通用的复苏方法,对于临床医生在实践中如何个性化地管理液体和血管加压剂的使用知之甚少。

目的

了解临床医生在实践中如何个性化地做出复苏决策。

设计、地点和参与者:这项对美国重症监护医学学会会员名单中的临床医生进行的调查研究于 2022 年 11 月至 2023 年 1 月进行。调查包含了 10 个脓毒症患者的病例,其中相关的临床因素(例如,接受的液体量和容量状态)是随机的。受访者选择下一步的治疗方案。数据分析于 2023 年 2 月至 9 月进行。

暴露

在线 Qualtrics 临床病例调查。

主要结果和措施

使用多变量逻辑回归,检验了临床因素与液体管理、血管加压剂启动和血管加压剂途径决策的关联。结果以调整后的比例(95%CI)呈现。

结果

在邀请的 11203 名临床医生中,有 550 名(4.9%;261 名男性[47.5%]和 192 名女性[34.9%];173 名具有>15 年实践经验[31.5%])至少完成了 1 个病例并被纳入分析。大多数是医生(337 名受访者[61.3%])和重症监护培训医生(369 名受访者[67.1%])。患者已经接受的液体量与复苏决策相关。在接受 1 L 液体后,调整后的 82.5%(95%CI,80.2%-84.8%)的受访者开了更多的液体,调整后的 55.0%(95%CI,51.9%-58.1%)的受访者开始使用血管加压剂。在接受 5 L 液体后,调整后的 17.5%(95%CI,15.1%-19.9%)的受访者开了更多的液体,而调整后的 92.7%(95%CI,91.1%-94.3%)的受访者开始使用血管加压剂。当患者检查发现干(即超负荷)和湿(即容量过载)容量状态时,更多的受访者开了液体(调整后的比例,66.9%[95%CI,62.5%-71.2%]与调整后的比例,26.5%[95%CI,22.3%-30.6%])。医疗史、呼吸状况、乳酸趋势和急性肾损伤与液体和血管加压剂决策有较小的关联。在 1127 个病例中的 1023 个(90.8%)患者没有中心通路的情况下,受访者愿意通过外周静脉导管开始使用血管加压剂。在患者已经接受外周去甲肾上腺素的情况下,当患者的去甲肾上腺素剂量更高(0.5 µg/kg/min)时,受访者更有可能放置中心静脉导管(调整后的比例,78.0%[95%CI,74.7%-81.2%]与 0.08 µg/kg/min(调整后的比例,25.2%[95%CI,21.8%-28.5%])和 24 小时后(调整后的比例,59.5%[95%CI,56.6%-62.5%]与 8 小时后(调整后的比例,47.1%[95%CI,44.0%-50.1%])。

结论和相关性

这些发现表明,接受的液体量是与持续液体和血管加压剂决策相关的主要因素,超过了许多其他临床因素。外周血管加压剂的使用很常见。未来旨在个性化复苏的研究必须考虑到液体量,并应纳入特定的工具来帮助临床医生个性化复苏。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d1c/11031682/14b04854739d/jamanetwopen-e247480-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d1c/11031682/a2389689aee7/jamanetwopen-e247480-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d1c/11031682/38d9adbb77f9/jamanetwopen-e247480-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d1c/11031682/14b04854739d/jamanetwopen-e247480-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d1c/11031682/a2389689aee7/jamanetwopen-e247480-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d1c/11031682/38d9adbb77f9/jamanetwopen-e247480-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d1c/11031682/14b04854739d/jamanetwopen-e247480-g003.jpg

相似文献

1
Understanding How Clinicians Personalize Fluid and Vasopressor Decisions in Early Sepsis Management.理解临床医生如何在早期脓毒症管理中个性化液体和血管加压药决策。
JAMA Netw Open. 2024 Apr 1;7(4):e247480. doi: 10.1001/jamanetworkopen.2024.7480.
2
Use and Outcomes of Peripheral Vasopressors in Early Sepsis-Induced Hypotension Across Michigan Hospitals: A Retrospective Cohort Study.密歇根州医院早期脓毒症性低血压外周血管加压药的使用和结局:一项回顾性队列研究。
Chest. 2024 Apr;165(4):847-857. doi: 10.1016/j.chest.2023.10.027. Epub 2023 Oct 26.
3
Evolving Management Practices for Early Sepsis-induced Hypoperfusion: A Narrative Review.早期脓毒症相关性低灌注的管理实践演变:叙述性综述。
Am J Respir Crit Care Med. 2023 May 15;207(10):1283-1299. doi: 10.1164/rccm.202209-1831CI.
4
Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension: A Randomized Clinical Trial.早期复苏方案对脓毒症和低血压成年患者院内死亡率的影响:一项随机临床试验
JAMA. 2017 Oct 3;318(13):1233-1240. doi: 10.1001/jama.2017.10913.
5
Early vs. Late Vassopressor therapy in the Management of Patients with Sepsis and Hypotension, A Multicenter Observational Study.早期与晚期血管加压素治疗脓毒症低血压患者:一项多中心观察性研究。
Arch Med Res. 2021 Nov;52(8):836-842. doi: 10.1016/j.arcmed.2021.07.001. Epub 2021 Jul 16.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).制定脓毒性休克的新定义并评估新的临床标准:用于第三次脓毒症和脓毒性休克国际共识定义(Sepsis-3)。
JAMA. 2016 Feb 23;315(8):775-87. doi: 10.1001/jama.2016.0289.
8
Delayed vasopressor initiation is associated with increased mortality in patients with septic shock.延迟血管升压药的使用与感染性休克患者死亡率的增加有关。
J Crit Care. 2020 Feb;55:145-148. doi: 10.1016/j.jcrc.2019.11.004. Epub 2019 Nov 9.
9
The Australasian Resuscitation In Sepsis Evaluation: FLUid or vasopressors In Emergency Department Sepsis, a multicentre observational study (ARISE FLUIDS observational study): Rationale, methods and analysis plan.澳大利亚脓毒症复苏评估:急诊科脓毒症中使用液体还是血管加压药,一项多中心观察性研究(ARISE 液体观察性研究):原理、方法和分析计划。
Emerg Med Australas. 2019 Feb;31(1):90-96. doi: 10.1111/1742-6723.13223. Epub 2019 Jan 22.
10
Emergency medicine updates: Management of sepsis and septic shock.急诊医学进展:脓毒症和脓毒性休克的管理
Am J Emerg Med. 2025 Apr;90:179-191. doi: 10.1016/j.ajem.2025.01.054. Epub 2025 Jan 22.

引用本文的文献

1
Norepinephrine ameliorates sepsis-associated acute kidney injury through inhibiting damage of renal tubular epithelium induced by macrophage inflammatory response.去甲肾上腺素通过抑制巨噬细胞炎症反应诱导的肾小管上皮损伤来改善脓毒症相关性急性肾损伤。
BMC Nephrol. 2025 Aug 29;26(1):498. doi: 10.1186/s12882-025-04421-8.
2
Early Positive Fluid Balance Associates with Increased Mortality in Neurological Critically Ill Patients: A 10-Year Cohort Study.早期正液体平衡与神经重症患者死亡率增加相关:一项10年队列研究
J Clin Med. 2025 Aug 5;14(15):5518. doi: 10.3390/jcm14155518.
3
Association between stress hyperglycemia ratio and acute kidney injury development in patients with sepsis: a retrospective study.

本文引用的文献

1
Use and Outcomes of Peripheral Vasopressors in Early Sepsis-Induced Hypotension Across Michigan Hospitals: A Retrospective Cohort Study.密歇根州医院早期脓毒症性低血压外周血管加压药的使用和结局:一项回顾性队列研究。
Chest. 2024 Apr;165(4):847-857. doi: 10.1016/j.chest.2023.10.027. Epub 2023 Oct 26.
2
Peripheral Administration of Norepinephrine: A Prospective Observational Study.去甲肾上腺素的外周给药:一项前瞻性观察性研究。
Chest. 2024 Feb;165(2):348-355. doi: 10.1016/j.chest.2023.08.019. Epub 2023 Aug 21.
3
How I personalize fluid therapy in septic shock?
脓毒症患者应激性高血糖比值与急性肾损伤发生之间的关联:一项回顾性研究。
Front Endocrinol (Lausanne). 2025 Apr 15;16:1542591. doi: 10.3389/fendo.2025.1542591. eCollection 2025.
4
Sepsis-Associated Acute Kidney Injury: Pathophysiology and Treatment Modalities.脓毒症相关急性肾损伤:病理生理学与治疗方式
Cureus. 2024 Dec 19;16(12):e75992. doi: 10.7759/cureus.75992. eCollection 2024 Dec.
如何在感染性休克中进行个体化液体治疗?
Crit Care. 2023 Mar 24;27(1):123. doi: 10.1186/s13054-023-04363-3.
4
Evolving Management Practices for Early Sepsis-induced Hypoperfusion: A Narrative Review.早期脓毒症相关性低灌注的管理实践演变:叙述性综述。
Am J Respir Crit Care Med. 2023 May 15;207(10):1283-1299. doi: 10.1164/rccm.202209-1831CI.
5
Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension.脓毒症性低血压的早期限制或宽松液体管理。
N Engl J Med. 2023 Feb 9;388(6):499-510. doi: 10.1056/NEJMoa2212663. Epub 2023 Jan 21.
6
A plea for personalization of the hemodynamic management of septic shock.呼吁个性化脓毒性休克的血流动力学管理。
Crit Care. 2022 Dec 1;26(1):372. doi: 10.1186/s13054-022-04255-y.
7
Restriction of Intravenous Fluid in ICU Patients with Septic Shock.ICU 脓毒性休克患者的静脉液体限制。
N Engl J Med. 2022 Jun 30;386(26):2459-2470. doi: 10.1056/NEJMoa2202707. Epub 2022 Jun 17.
8
Hospital Policies on Intravenous Vasopressor Administration and Monitoring: A Survey of Michigan Hospitals.密歇根州医院静脉血管加压药使用与监测的医院政策:一项调查
Ann Am Thorac Soc. 2022 Oct;19(10):1769-1772. doi: 10.1513/AnnalsATS.202203-197RL.
9
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.拯救脓毒症运动:2021年脓毒症和脓毒性休克国际管理指南
Crit Care Med. 2021 Nov 1;49(11):e1063-e1143. doi: 10.1097/CCM.0000000000005337.
10
Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: a systematic review and meta-analysis.外周静脉导管给药时与血管加压药物相关的不良事件:系统评价和荟萃分析。
Crit Care. 2021 Apr 16;25(1):146. doi: 10.1186/s13054-021-03553-1.